RxDoctor Payments Data

Georgia Shapiro, MD

Medical Oncology · Vero Beach, FLNPI 1609056308

Payments from drug & device makers

$9,357in general payments, 2019–2025

Across 434 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Merck$653
  • Bristol Myers Squibb$605
  • Johnson & Johnson$529
  • AstraZeneca$500
  • Astellas Pharma US Inc$474
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$8,62492%
  • Education$7338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,357 in reported general payments places this provider in the 35th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$5,634,742
Medicare patients
984
Services billed
292,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib68$1,022,722
PomalystPomalidomide27$710,951
Lenalidomide20$260,259
BrukinsaZanubrutinib15$216,281
JakafiRuxolitinib Phosphate11$188,242
Lupron DepotLeuprolide Acetate24$157,495
EliquisApixaban90$91,600
Sunitinib Malate11$80,503
Abiraterone Acetate20$73,722
Imatinib Mesylate19$15,916
Anastrozole281$6,919
Exemestane22$2,843
Ibandronate Sodium59$2,341
Levothyroxine Sodium107$1,611
Letrozole69$1,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$108$1,022,72268 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$311$710,95127 claims
Beigene USA, Inc.Brukinsa$21$216,28115 claims
Incyte CorporationJakafi$405$188,24211 claims
AbbVieLupron Depot, Synthroid$307$157,91835 claims
PfizerEliquis$1,196$91,60090 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,611107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →